4.6 Article

Antarctic Strain of Rhodotorula mucilaginosa UFMGCB 18,377 Attenuates Mucositis Induced by 5-Fluorouracil in Mice

Journal

PROBIOTICS AND ANTIMICROBIAL PROTEINS
Volume 14, Issue 3, Pages 486-500

Publisher

SPRINGER
DOI: 10.1007/s12602-021-09817-0

Keywords

Antarctica; Fungi; Probiotic; Yeasts; Rhodotorula mucilaginosa; Mucositis; 5-Fluorouracil

Funding

  1. Minas Gerais State Research Support Foundation (FAPEMIG) [APQ-00593-14]
  2. Coordination for the Improvement of Higher Education Personnel [CAPES 88887.136384/2017-00, 88887.314457/2019-00]
  3. CNPq PROANTAR [442258/20186]
  4. INCT Criosfera II
  5. FNDCT
  6. CAPES

Ask authors/readers for more resources

Mucositis, a severe side effect of chemotherapy drugs in cancer treatment, has no effective treatment currently. This study showed that oral administration of the Antarctic strain of Rhodotorula mucilaginosa UFMGCB 18,377 could effectively reduce mucositis induced by 5-FU.
Mucositis is one of the most strenuous side effects caused by chemotherapy drugs, such as 5-fluorouracil (5-FU), during the treatment of several types of cancers. The disease is so prevalent and aggressive that many patients cannot resist such symptoms. However, despite its frequency and clinical significance, there is no effective treatment to prevent or treat mucositis. Thus, the use of probiotics as an adjuvant for the treatment has gained prominence. In the present study, we evaluated the effectiveness of oral administration of the Antarctic strain of Rhodotorula mucilaginosa UFMGCB 18,377 as an alternative to minimize side effects of 5-FU-induced mucositis in mice. Body weight, food consumption, stool consistency, and presence of blood in the feces were assessed daily in mice orally treated or not with the yeast and submitted or not to experimental mucositis. Blood, bones, and intestinal tissues and fluid were used to determine intestinal permeability and immunological, microbiological, and histopathological parameters. Treatment with R. mucilaginosa UFMGCB 18,377 was able to decrease clinical signs of the disease, such as reduction of food intake and body weight loss, and also decreased the number of intestinal enterobacteria and intestinal length shortening. Additionally, treatment was able to decrease the levels of MPO and EPO activities and inflammatory infiltrates, as well as the histopathological lesions characteristic of mucositis in the jejunum and ileum. Results of the present study showed that the oral administration of R. mucilaginosa UFMGCB 18,377 protected mice against mucositis induced by 5-FU.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available